Zacks Research Has Negative View of OPKO Health Q2 Earnings

OPKO Health, Inc. (NASDAQ:OPK) – Equities research analysts at Zacks Research cut their Q2 2028 earnings per share estimates for shares of OPKO Health in a report released on Thursday, July 9th. Zacks Research analyst Team now anticipates that the biotechnology company will post earnings per share of ($0.05) for the quarter, down from their prior estimate of ($0.04). The consensus estimate for OPKO Health’s current full-year earnings is ($0.29) per share. Zacks Research also issued estimates for OPKO Health’s FY2028 earnings at ($0.19) EPS.

OPK has been the subject of a number of other reports. Wall Street Zen upgraded OPKO Health from a “sell” rating to a “hold” rating in a research note on Saturday, June 6th. Barrington Research cut shares of OPKO Health from an “outperform” rating to a “market perform” rating in a research note on Wednesday, April 29th. Finally, Weiss Ratings raised shares of OPKO Health from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, May 18th. Four investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, OPKO Health presently has an average rating of “Reduce” and an average target price of $1.55.

OPKO Health Price Performance

NASDAQ OPK opened at $1.35 on Monday. The stock’s 50-day moving average price is $1.35 and its 200-day moving average price is $1.27. The company has a quick ratio of 3.17, a current ratio of 3.61 and a debt-to-equity ratio of 0.28. OPKO Health has a 52 week low of $0.98 and a 52 week high of $1.61. The company has a market capitalization of $1.02 billion, a P/E ratio of -5.00 and a beta of 1.48.

OPKO Health (NASDAQ:OPK) last released its quarterly earnings results on Tuesday, April 28th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.07). OPKO Health had a negative return on equity of 16.78% and a negative net margin of 36.63%.The business had revenue of $124.20 million during the quarter, compared to analyst estimates of $130.51 million. During the same quarter in the previous year, the company posted ($0.10) earnings per share. OPKO Health’s revenue for the quarter was down 17.1% on a year-over-year basis.

Hedge Funds Weigh In On OPKO Health

A number of hedge funds have recently made changes to their positions in OPK. Zacks Investment Management bought a new stake in OPKO Health during the 4th quarter valued at approximately $27,000. StoneX Group Inc. bought a new position in OPKO Health in the 4th quarter worth approximately $27,000. Swiss Life Asset Management Ltd bought a new position in OPKO Health in the 3rd quarter worth approximately $30,000. Apella Capital LLC purchased a new stake in OPKO Health during the 1st quarter valued at approximately $34,000. Finally, Cibc World Markets Corp purchased a new stake in OPKO Health during the 4th quarter valued at approximately $34,000. Institutional investors own 64.63% of the company’s stock.

About OPKO Health

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.